DIVALPROEX SODIUM | N018723 | ABBVIE INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Abbott Laboratories (Clifford & Warnke) FDA-1986-P-0035 · 15 docket documents Abbott Laboratories filed this citizen petition on August 29, 1986, requesting that the FDA rule that DEPAKOTE (divalproex sodium) is entitled to ten years of exclusive marketing rights from its NDA approval date of March 10, 1983 (until March 10, 1993), and that the FDA refrain from making effectiv | 505(q) | 2025-11-06 | Denied | Abbott Laboratories (Clifford & Warnke) |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$7.45
per ea
Lowest NADAC/Unit
$2.05
per ea
Brand NDCs
3
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00074732713DEPAKOTE DR 500 MG TABLET | $7.45 | EA | Brand | $0.1643 | 2026-06-17 |
| 00074732613DEPAKOTE DR 250 MG TABLET | $4.05 | EA | Brand | $0.0862 | 2026-06-17 |
| 00074732513DEPAKOTE DR 125 MG TABLET | $2.05 | EA | Brand | $0.0541 | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.